These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18855664)

  • 1. Synthetic glycolipid ligands for human iNKT cells as potential therapeutic agents for immunotherapy.
    Araki M; Miyake S; Yamamura T
    Curr Med Chem; 2008; 15(23):2337-45. PubMed ID: 18855664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tailored design of NKT-stimulatory glycolipids for polarization of immune responses.
    Hung JT; Huang JR; Yu AL
    J Biomed Sci; 2017 Mar; 24(1):22. PubMed ID: 28335781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic potential for ceramide-based activators of iNKT cells.
    Berkers CR; Ovaa H
    Trends Pharmacol Sci; 2005 May; 26(5):252-7. PubMed ID: 15860372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avidity of CD1d-ligand-receptor ternary complex contributes to T-helper 1 (Th1) polarization and anticancer efficacy.
    Wu TN; Lin KH; Chang YJ; Huang JR; Cheng JY; Yu AL; Wong CH
    Proc Natl Acad Sci U S A; 2011 Oct; 108(42):17275-80. PubMed ID: 21987790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. iNKT-cell responses to glycolipids.
    Parekh VV; Wilson MT; Van Kaer L
    Crit Rev Immunol; 2005; 25(3):183-213. PubMed ID: 16048435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotion or Suppression of Murine Intestinal Polyp Development by iNKT Cell Directed Immunotherapy.
    Wang Y; Sedimbi SK; Löfbom L; Besra GS; Porcelli SA; Cardell SL
    Front Immunol; 2019; 10():352. PubMed ID: 30881361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Invariant natural killer T (iNKT) cells in asthma: a novel insight into the pathogenesis of asthma and the therapeutic implication of glycolipid ligands for allergic diseases.
    Oki S; Miyake S
    Allergol Int; 2007 Mar; 56(1):7-14. PubMed ID: 17259804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulatory Functions of α-GalCer and a Derivative, α-Carba-GalCer.
    Satoh M; Iwabuchi K
    Methods Mol Biol; 2023; 2613():1-11. PubMed ID: 36587066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
    Wu L; Gabriel CL; Parekh VV; Van Kaer L
    Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NKT cell-stimulating synthetic glycolipids as potential therapeutics for autoimmune disease.
    Yamamura T; Miyamoto K; Illés Z; Pál E; Araki M; Miyake S
    Curr Top Med Chem; 2004; 4(5):561-7. PubMed ID: 14965307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.
    King LA; Lameris R; de Gruijl TD; van der Vliet HJ
    Front Immunol; 2018; 9():1519. PubMed ID: 30013569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of invariant natural killer T (iNKT) cells in systemic lupus erythematosus.
    Godó M; Sessler T; Hamar P
    Curr Med Chem; 2008; 15(18):1778-87. PubMed ID: 18691038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel thioglycoside analogs of α-galactosylceramide stimulate cytotoxicity and preferential Th1 cytokine production by human invariant natural killer T cells.
    Melo AM; Zhang L; Dockry ÉF; Petrasca A; Ghnewa YG; Breen EP; Morrissey ME; O'Reilly C; Bruen R; O'Meara A; Lysaght J; Zhu X; Doherty DG
    Glycobiology; 2018 Jul; 28(7):512-521. PubMed ID: 29688330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of glycolipid ligands for natural killer (NK) T cells in the suppression of autoimmune diseases.
    Miyake S; Yamamura T
    Curr Drug Targets Immune Endocr Metabol Disord; 2005 Sep; 5(3):315-22. PubMed ID: 16178791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Species-specific activity of glycolipid ligands for invariant NKT cells.
    Dangerfield EM; Cheng JM; Knight DA; Weinkove R; Dunbar PR; Hermans IF; Timmer MS; Stocker BL
    Chembiochem; 2012 Jun; 13(9):1349-56. PubMed ID: 22639457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing and curing citrulline-induced autoimmune arthritis in a humanized mouse model using a Th2-polarizing iNKT cell agonist.
    Walker KM; Rytelewski M; Mazzuca DM; Meilleur SA; Mannik LA; Yue D; Brintnell WC; Welch I; Cairns E; Haeryfar SM
    Immunol Cell Biol; 2012 Jul; 90(6):630-9. PubMed ID: 21912419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological activities of amino acids functionalized α-GalCer analogues.
    Ma W; Bi J; Zhao C; Zhang Z; Liu T; Zhang G
    Bioorg Med Chem; 2020 Jan; 28(1):115141. PubMed ID: 31786009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Invariant NKT in Autoimmune Liver Disease: Can Vitamin D Act as an Immunomodulator?
    Smyk DS; Mavropoulos A; Mieli-Vergani G; Vergani D; Lenzi M; Bogdanos DP
    Can J Gastroenterol Hepatol; 2018; 2018():8197937. PubMed ID: 30046564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4"-O-Alkylated α-Galactosylceramide Analogues as iNKT-Cell Antigens: Synthetic, Biological, and Structural Studies.
    Janssens J; Bitra A; Wang J; Decruy T; Venken K; van der Eycken J; Elewaut D; Zajonc DM; van Calenbergh S
    ChemMedChem; 2019 Jan; 14(1):147-168. PubMed ID: 30556652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycolipids as immune modulatory tools.
    Lalazar G; Preston S; Zigmond E; Ben Yáacov A; Ilan Y
    Mini Rev Med Chem; 2006 Nov; 6(11):1249-53. PubMed ID: 17100636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.